Treatment of moderate-to-severe active SLE patients without cerebral or renal involvement with the BTK inhibitor fenebrutinib reduced CD19+ B cells, anti-dsDNA antibody titer, and BTK-dependent signature in plasmablasts, but the primary clinical efficacy endpoint (SRI-4) was not met108. This evidence concerns the gene BTK and systemic lupus erythematosus.